Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

In fact, C. diff infections often spring up because the bacteria take advantage of a weakened microbiome following treatment with antibiotics for other diseases. “Treatment of C. difficile ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

There are about 500,000 cases of C. difficile each year; about one in six people with the infection will see it come back within two to eight weeks of the initial infection. “Treatment of C.

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...

When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Once C-diff is in the ascendancy it can be very hard to shift – the traditional treatment is antibiotics but a significant number of patients do not respond and are left with relentless and ...